

### REMARKS

Claims 7 – 28 are pending and rejected in this application. Claim 7 is amended to include the language of the now cancelled Claim 3 that was considered allowable by the Examiner in the office action of June 5, 2002. Claims 8 – 28 were amended to replace “method” in the preamble with “the lens care solution” to properly refer to solution of Claim 7. No new matter is added.


The Examiner brought two newly found references to Applicant’s attention in an Advisory Action mailed July 20, 2005. These references are U.S. Patents 5,888,950 to Potini, et al. and 4,046,706 to Krezanoski. Applicant submits that both Potini, et al. and Krezanoski teach only imidazole derivative surfactants and they do not suggest the use of imidazole itself. The Aldrich Handbook defines imidazole as shown in the attached appendix (“Imidazole.” The Aldrich Handbook, 2005-2006 US ed. Sigma-Aldrich Co., 2005), which definition is not taught by the references. In contrast, the present application claims imidazole and not an imidazole derivative. Therefore, Applicant respectfully submits that neither Potini, et al. nor Krezanoski renders obvious the invention as now claimed whether viewed singly or in combination.

The Examiner is invited to call the undersigned practitioner if he has any matters to address that will facilitate allowance of the application.

Applicants respectfully request favorable consideration and that a timely Notice of Allowance be issued in this case.

In the event that Applicant has overlooked the need for an extension of time, additional extension of time, payment of fee, or additional payment of fee, Applicants hereby conditionally petition therefore and authorize that any changes be made to Deposit Account No.: 50-3010.

Respectfully submitted,  
HISCOCK & BARCLAY, LLP

By:   
William M. Hall  
Reg. No. 52,985  
2000 HSBC Plaza  
Rochester, NY 14604  
Tel: (585) 295-4481  
Fax: (585) 295-8449

(Continuation of)  
Igepal® CO-890

®Registered trademark of GAF Corp.

✗ R: 37-41 S: 26-39 RTECS# AX0247000; TSCA Fp: 100°C (212°F)

238678-100G	glass btl 100 g	21.90
238678-500G	flint glass 500 g	65.50

Igepal® CO-990

Polyoxyethylene(100) nonylphenyl ether, branched  
[68412-54-4] (C<sub>2</sub>H<sub>4</sub>O)<sub>n</sub> · C<sub>15</sub>H<sub>24</sub>O, n~100average M<sub>n</sub> ~4,626

Merck 13,6711


mp	57 to 58 °C
HLB	19

®Registered trademark of GAF Corp.

✗ R: 37-41 S: 26-39 RTECS# AX0247000; TSCA Fp: 100°C (212°F)

238686-100G	poly btl 100 g	21.40
238686-500G	poly btl 500 g	63.80

Igepal® DM-970

Polyoxyethylene(150) dinonyl-  
phenyl ethermp 59 to 61 °C  
HLB 19


®Registered trademark of GAF Corp.

✗ R: 36/37/38 S: 26-37/39; TSCA Fp: 113°C (235°F)

238694-500G	poly btl 500 g	26.10
-------------	----------------	-------

IDQ, see 1-isobutoxycarbonyl-2-isobutoxy-1,2-dihydroquinoline  
Page 1434

M(α), N-(lim)-Di-Boc-L-histidine methyl ester, 97%

[17791-51-4] C<sub>17</sub>H<sub>27</sub>N<sub>3</sub>O<sub>6</sub>  
FW 369.41mp 113 to 116 °C  
S: 22-24/25

550752-1G	glass btl 1 g	18.30
550752-5G	glass btl 5 g	64.60

imidazole

[288-32-4] C<sub>3</sub>H<sub>4</sub>N<sub>2</sub> FW 68.08

Excellent for buffers in the range of pH 6.2-7.8

Merck 13,4935; Beil. 23,V,4,191; Fieser 1,492; 2,220

bp 256 °C

pKa (25 °C) 6.95

mp 88 to 91 °C

vp &lt;1 mm Hg (20 °C)

R: 22-34 S: 26-36/37/39-45 RTECS# N13325000  
Fp: 145°C (293°F)

ACS reagent, ≥99%

pH 9.5-11.0 (25 °C, 5% in solution) Fe ≤0.001%

ign. residue ≤0.1%

12399-100G	100 g	23.40
12399-500G	500 g	77.30

ReagentPlus™, 99%

Used as an antimetabolite and as an inhibitor of histamine. Also has many synthetic uses.

1202-1G	glass btl 1 g	7.90
1202-5G	glass btl 5 g	8.52
1202-100G	poly btl 100 g	21.52
1202-500G	poly btl 500 g	70.30
1202-2KG	poly btl 2 kg	156.52

imidazole-<sup>15</sup>N<sub>2</sub>[74362-46-2] C<sub>3</sub>H<sub>4</sub><sup>15</sup>N<sub>2</sub> FW 70.0698 atom % <sup>15</sup>N

98% (CP)

bp 256 °C mp 89 to 91 °C

R: 22-34 S: 22-26-36/37/39-45 Fp: 113°C (235°F)

489751-100MG	glass btl 100 mg	522.00
--------------	------------------	--------

imidazole-d<sub>4</sub>[6923-01-9] C<sub>3</sub>D<sub>4</sub>N<sub>2</sub> FW 72.10

98 atom % D

Beil. 23,IV,568

mp 89 to 91 °C

R: 22-34 S: 22-26-36/37/39-45

437298-250MG	glass btl 250 mg	74.50
437298-1G	glass btl 1 g	205.90


imidazole hydrochloride, 98%

[1467-16-9] C<sub>3</sub>H<sub>4</sub>N<sub>2</sub> · HCl FW 104.54

Beil. 23,V,4,196

mp 158 to 161 °C

✗ R: 36/38 S: 26-36 Hygroscopic



302007-5G	glass btl 5 g	19.00
302007-100G	glass btl 100 g	26.40
302007-500G	glass btl 500 g	84.10

imidazole sodium derivative

Imidazolisodium

[5587-42-8] C<sub>3</sub>H<sub>3</sub>N<sub>2</sub>Na FW 90.06

technical grade

Beil. 23,II,35

mp 284 °C (dec.)

R: 20/21/22-34 S: 26-36/37/39-45

197637-10G	glass btl 10 g	65.30
197637-50G	glass btl 50 g	220.00


imidazole trifluoromethanesulfonate salt, 97%

[29727-06-8] C<sub>3</sub>H<sub>4</sub>N<sub>2</sub> · CHF<sub>3</sub>SO<sub>3</sub>

FW 218.15

mp 189 to 193 °C

✗ R: 36/37/38 S: 26-36



515876-5G	glass btl 5 g	19.50
515876-25G	glass btl 25 g	64.80

4-imidazoleacetic acid hydrochloride, 98%


[3257-69-2] C<sub>5</sub>H<sub>6</sub>N<sub>2</sub>O<sub>2</sub> · HCl

FW 162.57

Beil. 25,IV,742

mp 218 to 222 °C

S: 22-24/25



219991-250MG	glass btl 250 mg	31.90
219991-1G	glass btl 1 g	88.10
219991-5G	glass btl 5 g	338.50